Literature DB >> 4101498

Melioidosis and chronic granulomatous disease.

M J Tarlow, J Lloyd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4101498      PMCID： PMC1811937     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN： 0035-9157


× No keyword cloud information.
  5 in total

1.  SEROLOGIC STUDIES ON SUBCLINICAL MELIOIDOSIS.

Authors:  C NIGG
Journal:  J Immunol       Date:  1963-07       Impact factor: 5.422

2.  A newly defined X-linked trait in man with demonstration of the Lyon effect in carrier females.

Authors:  D B Windhorst; B Holmes; R A Good
Journal:  Lancet       Date:  1967-04-08       Impact factor: 79.321

3.  Chronic granulomatous disease: quantitative clinicopathological relationships.

Authors:  E N Thompson; J F Soothill
Journal:  Arch Dis Child       Date:  1970-02       Impact factor: 3.791

4.  Melioidosis: a report of ten cases.

Authors:  R N Thin; M Brown; J B Stewart; C J Garrett
Journal:  Q J Med       Date:  1970-01

5.  In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood.

Authors:  P G Quie; J G White; B Holmes; R A Good
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808
  5 in total
  9 in total

1.  Burkholderia pseudomallei infection in chronic granulomatous disease.

Authors:  Raffaele Renella; Jean-Marie Perez; Sylvie Chollet-Martin; Sabine Sarnacki; Alain Fischer; Stéphane Blanche; Jean-Laurent Casanova; Capucine Picard
Journal:  Eur J Pediatr       Date:  2005-12-03       Impact factor: 3.183

Review 2.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Infection Profile in Chronic Granulomatous Disease: a 23-Year Experience from a Tertiary Care Center in North India.

Authors:  Amit Rawat; Pandiarajan Vignesh; Avinash Sharma; Jitendra K Shandilya; Madhubala Sharma; Deepti Suri; Anju Gupta; Vikas Gautam; Pallab Ray; Shivaprakash M Rudramurthy; Arunaloke Chakrabarti; Kohsuke Imai; Shigeaki Nonoyama; Osamu Ohara; Yu L Lau; Surjit Singh
Journal:  J Clin Immunol       Date:  2017-03-22       Impact factor: 8.317

4.  Artificial ventilation for neurological disease: retrospective analysis 1972-81.

Authors:  J G Douglas; R J Fergusson; G K Crompton; I W Grant
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-18

5.  Interaction of Interferon gamma-induced reactive oxygen species with ceftazidime leads to synergistic killing of intracellular Burkholderia pseudomallei.

Authors:  Kara Mosovsky; Ediane Silva; Ryan Troyer; Katie Propst-Graham; Steven Dow
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

6.  Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei.

Authors:  P Santanirand; V S Harley; D A Dance; B S Drasar; G J Bancroft
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

7.  Characterization of Burkholderia pseudomallei Strains Using a Murine Intraperitoneal Infection Model and In Vitro Macrophage Assays.

Authors:  Susan L Welkos; Christopher P Klimko; Steven J Kern; Jeremy J Bearss; Joel A Bozue; Robert C Bernhards; Sylvia R Trevino; David M Waag; Kei Amemiya; Patricia L Worsham; Christopher K Cote
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

8.  Delineating the importance of serum opsonins and the bacterial capsule in affecting the uptake and killing of Burkholderia pseudomallei by murine neutrophils and macrophages.

Authors:  Minal Mulye; Michael P Bechill; William Grose; Viviana P Ferreira; Eric R Lafontaine; R Mark Wooten
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

9.  Characterization of in vitro phenotypes of Burkholderia pseudomallei and Burkholderia mallei strains potentially associated with persistent infection in mice.

Authors:  R C Bernhards; C K Cote; K Amemiya; D M Waag; C P Klimko; P L Worsham; S L Welkos
Journal:  Arch Microbiol       Date:  2016-10-13       Impact factor: 2.552
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.